Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol for prevention of post-ERCP pancreatitis
ACTRN12611000182998Phase 2Active, not recruiting
- Sponsor
- Mohammad Abbasinazari
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of allopurinol in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) and pancreatitis (2 arms), sponsored by Mohammad Abbasinazari. Primary endpoint: Plasma amylase level. Started Feb 2010; status: active, not recruiting.
02
Drugs
allopurinol
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)pancreatitis
Beyond the preview
Go deeper on ACTRN12611000182998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000182998.